Hotline:
+ 49 (0) 2204 2918806

Estudios en la categoría Medicamentos/Fármacos

Artículo 1 hasta 10 de 7745

  1. 1
  2. | 2
  3. | 3
  4. | 4
  5. | 5
  6. | 6
  7. | 7
  8. | 8
  9. | 9
  10. | 10
  11. ...
  12. | 775
  1. Precio neto*
    Año
  2. US$ 284,11
    2015
    Für diese Studie liegt keine Bewertung vor.

    Nawaloka Hospitals Private Limited (NHL.N0000) - Financial and Strategic SWOT Analysis Review

    GlobalData
    25 Pages
    This comprehensive SWOT profile of Nawaloka Hospitals Private Limited provides you an in-depth strategic analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threat
    Englisch | Zukunftsanalyse | Código: 85543
  3. US$ 2.367,60
    2014
    Für diese Studie liegt keine Bewertung vor.

    Degenerative Scoliosis Global Clinical Trials Review, H1, 2014

    GlobalData
    51 Páginas
    GlobalData's clinical trial report, “Degenerative Scoliosis Global Clinical Trials Review, H1, 2014" provides data on the Degenerative Scoliosis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Degenerative Scoliosis. It includes an overview of the trial numbers and their re
    Englisch | Zukunftsanalyse | Código: 403376
  4. US$ 1.420,56
    2012
    Für diese Studie liegt keine Bewertung vor.

    Viral Genetics, Inc. – Product Pipeline Review – 2012

    Global Markets Direct
    29 Páginas
    Introduction Global Market Direct’s pharmaceuticals report, “Viral Genetics, Inc. - Product Pipeline Review - 2012” provides data on the Viral Genetics, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant pr
    Englisch | Report | Código: 318071
  5. US$ 236,76
    2014
    Für diese Studie liegt keine Bewertung vor.

    Lytix Biopharma AS - Pharmaceuticals & Healthcare - Deals and Alliances Profile

    GlobalData
    18 paginás
    Lytix Biopharma AS (Lytix) is a biopharmaceutical company. Its products under clinical development include LTX-109, and LTX-315. The company’s LTX-109 is used for the treatment of melanoma; and LTX-315 adjuvance is a Phase-I clinical stage candidate that is developed as a GV1001 telomerase vaccine for inhibiting tyrosine kinase. The com
    Englisch | Zukunftsanalyse | Código: 163175
  6. US$ 236,76
    2014
    Für diese Studie liegt keine Bewertung vor.

    Idenix Pharmaceuticals, Inc. (IDIX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

    GlobalData
    33 Páginas
    Idenix Pharmaceuticals, Inc. (Idenix) is a biopharmaceutical. It carries out the discovery and development of drug candidates for the treatment of human viral diseases. The company's research and development activities are focused on treating infections caused by hepatitis C virus (HCV). Its pipeline products include samatasvir indicated
    Englisch | Zukunftsanalyse | Código: 359718
  7. US$ 1.894,08
    2013
    Für diese Studie liegt keine Bewertung vor.

    Sarcomas – Pipeline Review, H1 2013

    Global Markets Direct
    292 Páginas
    Introduction Global Markets Direct’s, 'Sarcomas - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Sarcomas, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key player
    Englisch | Report | Código: 324505
  8. US$ 3.309,90
    2014
    Für diese Studie liegt keine Bewertung vor.

    Xeljanz (Ulcerative Colitis) - Forecast and Market Analysis to 2022

    GlobalData
    59 Páginas
    During the forecast period from 2012-2022, the growth of the UC market will be driven largely by the entry of Johnson & Johnson’s (J&J’s) Simponi and Takeda’s Entyvio, which will lead to an increase in the overall number of patients being treated with biologics in the US, 5EU, Japan, and Canada. Another key event affecting the UC ma
    Englisch | Zukunftsanalyse | Código: 402643
  9. US$ 1.894,08
    2013
    Für diese Studie liegt keine Bewertung vor.

    Pneumonia – Pipeline Review, H1 2013

    Global Markets Direct
    160 Páginas
    Introduction Global Markets Direct’s, 'Pneumonia - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Pneumonia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key play
    Englisch | Report | Código: 318711
  10. US$ 6.624,54
    2012
    Für diese Studie liegt keine Bewertung vor.

    FluBlok (Seasonal Influenza Vaccines) Forecast and Market Analysis

    GlobalData
    68 Páginas
    Introduction GlobalData has released its new PharmaPoint Drug Evaluation report, FluBlok (Seasonal Influenza Vaccines) Forecast and Market Analysis. Seasonal Influenza is a respiratory infection caused by influenza virus that results in mild to severe symptoms, such as fever, cold and cough. The market is heavily driven by the sales of pr
    Englisch | Report | Código: 329193
  11. US$ 2.367,60
    2013
    Für diese Studie liegt keine Bewertung vor.

    Low Cardiac Output Syndrome Global Clinical Trials Review, H1, 2013

    GlobalData
    62 Páginas
    Introduction GlobalData's clinical trial report, “Low Cardiac Output Syndrome Global Clinical Trials Review, H1, 2013" provides data on the Low Cardiac Output Syndrome clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Low Cardiac Output Syndrome. It includes an overview of th
    Englisch | Report | Código: 329579

Artículo 1 hasta 10 de 7745

  1. 1
  2. | 2
  3. | 3
  4. | 4
  5. | 5
  6. | 6
  7. | 7
  8. | 8
  9. | 9
  10. | 10
  11. ...
  12. | 775